Bredt David 4
4 · Rapport Therapeutics, Inc. · Filed Jan 5, 2026
Insider Transaction Report
Form 4
Bredt David
Chief Scientific Officer
Transactions
- Award
Common Stock
2025-12-31−18,000→ 410,642 total - Sale
Common Stock
2025-12-31$30.05/sh−6,567$197,338→ 404,075 total
Footnotes (3)
- [F1]On December 4, 2024, the Reporting Person was granted performance-based restricted stock units ("PSUs") subject to the satisfaction of specified performance criteria as of December 31, 2025. The issuers Compensation Committee confirmed that the performance criteria had been met, resulting in the vesting of such PSUs effective December 31, 2025.
- [F2]Represents shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting and settlement of restricted stock units, and does not represent a discretionary trade by the reporting person.
- [F3]The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $30.04 to $30.05. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.